This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Hereditary myopathy NOS (primary disorder of muscle, unspecified)Primary Disorder of Muscle, Unspecified (Hereditary Myopathy NOS)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: G71.9 | Special Copayment Reduction: V012 (5 years)
B. SynonymsPrimary disorder of muscle, unspecified, hereditary myopathy NOS, Primary myopathy unspecified
C. Adult onsetLikelihood of first onset in adulthood: moderate — age of onset varies by subtype; congenital·childhood onset is common, but adult-onset subtypes also exist
1. HistoryHistory of the development of the myopathy concept, from Duchenne's description of muscular dystrophy in the 19th century to current NGS-based classification
2. CausesGene mutations in muscle fiber structural proteins·enzymes·ion channels, etc.; hundreds of related genes identified
3. GeneticsVarious inheritance patterns, including autosomal dominant, autosomal recessive, X-linked, and mitochondrial inheritance
4. EpidemiologyOverall prevalence of myopathies about 5–15 per 100,000; G71.9 is a residual category covering cases with unconfirmed classification
5. PathophysiologyDiverse pathophysiology, including muscle fiber structural defects, impaired energy metabolism, protein aggregation, and abnormal autophagy
6. SymptomsMuscle weakness (symmetric·proximal predominant), exercise intolerance, myalgia, respiratory muscle involvement, dysphagia
7. SignsProximal muscle weakness, Gowers sign, scapular winging, findings of cardiopulmonary involvement
8. ScreeningSerum CK measurement; neonatal metabolic screening; electromyography, muscle MRI
9. DiagnosisMuscle biopsy (light·electron microscopy, immunochemistry), NGS myopathy panel or whole exome/genome analysis
10. TreatmentTargeted therapy by causative gene (some), rehabilitation·orthoses·respiratory support; steroids (some with accompanying inflammation)
11. PrognosisPrognosis varies by subtype·age of onset·presence of respiratory involvement; some progress slowly, some die early
12. PreventionGenetic counseling, preimplantation genetic testing (PGT), prenatal diagnosis; family screening
13. ReferencesSewry CA et al. (2019) and 9 other key papers

1. History

Clinical recognition of myopathy dates back to the mid-19th century. Guillaume-Benjamin-Amand Duchenne, in first describing progressive pseudohypertrophic muscular dystrophy (Duchenne muscular dystrophy, DMD) in detail in 1861, argued that a structural abnormality of the muscle itself was the fundamental cause of the disease. Subsequently, Wilhelm Erb reported limb-girdle muscular dystrophy in 1884, and Hans Steinert reported myotonic dystrophy in 1909, each as an independent clinical entity. Initially, classification was based only on clinical phenotype and histological findings, but with the introduction of electron microscopy in the 1950s–60s, ultrastructural abnormalities of muscle fibers were identified and a separate category, congenital myopathy, was established.

Advances in molecular genetics fundamentally changed the classification system of myopathies. The identification in 1987 by Louis Kunkel et al. of dystrophin, the causative gene of DMD, was a turning point in neuromuscular disease genetics. Subsequently, dozens of myopathy-causing genes, including calpain-3, dysferlin, the sarcoglycan family, titin, and lamin A/C (LMNA), were discovered one after another in the 1990s–2000s. The spread of next-generation sequencing (NGS) technology in the 2010s introduced into clinical practice myopathy panel testing that analyzes hundreds of genes simultaneously, and further whole exome sequencing (WES)·whole genome sequencing (WGS). As a result, causative genes are being identified in many cases that were previously unclassifiable, and ICD-10 G71.9 ("primary disorder of muscle, unspecified") functions as an intermediate code before the diagnostic process is complete, or as a residual category applied to cases whose cause is not identified despite all molecular·histological testing. Currently, standardized diagnostic pathways are being established centered on specialized neuromuscular disease centers, and internationally, registries such as the TREAT-NMD network are contributing to understanding the natural history and laying the foundation for clinical trials.

2. Causes

The cause of hereditary myopathies classified as G71.9 is essentially a pathogenic variant in a gene encoding a protein involved in the structure·function of muscle fibers. Muscle cells depend on the normal expression and function of diverse molecules, including contractile proteins (actin, myosin heavy chain, troponin, tropomyosin), cytoskeletal proteins (dystrophin, spectrin, desmin, vimentin), nuclear envelope proteins (lamin A/C, emerin), extracellular matrix-binding proteins (sarcoglycans, dystroglycan, collagen VI), proteases (calpain-3), membrane repair proteins (dysferlin), autophagy-related proteins (LAMP2), and glycosylation enzymes (GnT-II, the group of enzymes related to alpha-DG glycosylation). If even one of these proteins is abnormal, failure to maintain muscle fiber integrity, abnormal energy supply, or accumulation of toxic proteins occurs, leading to muscle weakness·atrophy.

To date, more than 450 genes are known to be associated with neuromuscular diseases, and genes specific to myopathies alone exceed 200. Representative groups of causative genes include ① dystrophinopathies (DMD), ② limb-girdle muscular dystrophies (LGMD; CAPN3, DYSF, SGCA/B/C/D, FKRP, ANO5, etc.), ③ congenital myopathies (RYR1, NEB, ACTA1, TPM2/3, TTN, DNM2, etc.), ④ distal myopathies (MYH7, GNE, MATR3, etc.), ⑤ Emery-Dreifuss muscular dystrophy (LMNA, EMD, FHL1), ⑥ congenital muscular dystrophies (COL6A1/A2/A3, LAMA2, ITGA7, FKTN, etc.), ⑦ lysosomal storage myopathies (GAA deficiency-Pompe disease), and ⑧ mitochondrial myopathies. The G71.9 code is applied provisionally when a case does not fall into any of these specific classifications or when molecular diagnosis is not complete.

3. Genetics

Hereditary myopathies are a highly heterogeneous group of diseases in terms of inheritance pattern. The main inheritance patterns are as follows.

Autosomal dominant (AD): A single pathogenic variant is sufficient to cause disease. This includes myotonic dystrophy (DMPK, CNBP), facioscapulohumeral muscular dystrophy (FSHD, D4Z4 repeat contraction), some congenital myopathies (TPM2, TPM3 heterozygous variants), some limb-girdle muscular dystrophies (LGMD1 series), and Emery-Dreifuss muscular dystrophy (LMNA). When no family history is identified, de novo variants should also be considered.

Autosomal recessive (AR): The most frequent inheritance pattern, requiring pathogenic variants on both alleles. Representative examples are limb-girdle muscular dystrophies (LGMD2 series; CAPN3, DYSF, FKRP, ANO5, etc.), congenital muscular dystrophies (COL6A1-A3, LAMA2), congenital myopathies (NEB, RYR1 AR variants), and Pompe disease (GAA). Prevalence is high in populations with frequent consanguineous marriage.

X-linked: Includes DMD and Becker muscular dystrophy (DMD gene defect), Emery-Dreifuss muscular dystrophy (EMD), and Danon disease (LAMP2). It presents severely in males, and female carriers may also show some symptoms.

Mitochondrial inheritance: Mitochondrial myopathies due to mitochondrial DNA (mtDNA) variants or nuclear gene (POLG, TWNK, etc.) variants show maternal inheritance or non-Mendelian inheritance patterns. They are often accompanied by multisystem involvement beyond muscle (heart, nervous system, endocrine system).

From a clinical genetics perspective, the rate at which variants of uncertain significance (VUS) are reported even after NGS analysis is high, and in such cases additional interpretation through parental segregation study, functional assay, analysis of protein expression in muscle biopsy, etc. is needed. The diagnostic yield of whole exome sequencing in symptomatic patients is reported at about 40–60%.

4. General epidemiology

Taken as a whole, hereditary myopathies have an estimated worldwide prevalence of about 5–15 per 100,000, but this varies greatly by disease. DMD, the most common hereditary myopathy, has a prevalence of about 20 per 100,000 male births, and myotonic dystrophy about 5–20. Limb-girdle muscular dystrophy (LGMD) overall is estimated at about 2–10 per 100,000, and the frequency of specific subtypes differs markedly by country and ethnic group (e.g., the population effect of LGMD R5/LGMD2C is markedly higher in North African populations). Congenital myopathies (nemaline, central core, etc.) are rare, at about 0.1–2 per 100,000 births.

Epidemiological data for the G71.9 ("primary disorder of muscle, unspecified") code itself are limited, and because this category corresponds to an intermediate state before diagnosis is confirmed, actual prevalence is difficult to estimate. Korean Special Copayment Reduction data show a steadily increasing number of patients registered with rare neuromuscular diseases, reflecting an increase in newly confirmed cases as diagnostic technology advances. Age of onset ranges from the congenital period to adulthood depending on subtype, and except for X-linked forms, the sex distribution is generally even. Because the diagnostic yield is significantly higher when a family member has similar symptoms, the importance of family screening is emphasized.

5. Pathophysiology

The pathophysiology of hereditary myopathies varies by causative gene but converges on several common pathways of cell injury.

Muscle fiber structural defects: When the cytoskeleton-basement membrane linkage is damaged, as in defects of the dystrophin-glycoprotein complex (DGC) or collagen VI, the fibers become vulnerable to mechanical stress during contraction, the sarcolemma ruptures repeatedly, and a cycle of inflammation·necrosis·fibrosis is formed.

Contractile protein abnormalities: Variants in contractile apparatus proteins such as actin (ACTA1), myosin heavy chain (MYH7), nebulin (NEB), and tropomyosin (TPM2/3) cause reduced efficiency of force generation and abnormal sarcomere structure. Under light microscopy they appear as characteristic structures such as rod bodies, central cores, and minicores.

Impaired protein homeostasis: Desminopathies and other intermediate filament protein variants overload the autophagy-lysosome pathway through the formation of protein aggregates, and in Danon disease, accumulation of autophagosomes due to LAMP2 deficiency directly damages muscle cells.

Abnormal energy metabolism: In mitochondrial myopathies, deficiency of oxidative phosphorylation complexes reduces ATP production, and oxidative stress accelerates muscle fiber damage. Deficiency of the lysosomal glycogen-degrading enzyme (GAA) (Pompe disease) destroys muscle fiber structure through intralysosomal glycogen accumulation.

Nuclear envelope defects: LMNA variants cause fragility of nuclear envelope structure together with abnormal mechanosensing signal transduction and defects in cell differentiation, increasing myocyte nuclear damage and cell death.

Membrane repair defects: Dysferlin (DYSF) is involved in membrane repair through calcium-dependent vesicle fusion after sarcolemmal injury. In DYSF deficiency, failure to repair membrane damage leads to cumulative repeated muscle fiber necrosis.

6. Symptoms

The symptom patterns of hereditary myopathies vary greatly by subtype, but skeletal muscle weakness·atrophy is central. Typical symptom patterns are as follows.

Muscle weakness: The most common and important symptom. Proximal predominance (proximal > distal) is usual, but in distal myopathies (Welander, Nonaka, Miyoshi, etc.) the distal muscles are involved first. It is often bilaterally symmetric, but there are exceptions with an asymmetric pattern, such as facioscapulohumeral (FSHD) muscular dystrophy. Proximal weakness presents as difficulty climbing stairs, difficulty rising from a chair, and difficulty raising the arms.

Exercise intolerance and fatigue: Prominent in some subtypes (mitochondrial myopathy, Pompe disease, metabolic myopathies). Patients may show extreme fatigue, myalgia, and myoglobinuria (dark brown urine) after brief exercise.

Respiratory muscle involvement: Respiratory failure may develop due to weakness of the diaphragm and intercostal muscles. Respiratory involvement appears early in congenital myopathies (RYR1 series), some LGMD subtypes, and Emery-Dreifuss muscular dystrophy, and sleep-disordered breathing is sometimes the first sign.

Dysphagia and facial muscle weakness: In some subtypes (myotonic dystrophy, OPMD, some congenital myopathies), dysphagia, dysarthria, and extraocular muscle paralysis (ptosis, ophthalmoplegia) are present.

Myocardial involvement: In Emery-Dreifuss muscular dystrophy, LMNA variant-related myopathy, some LGMDs (SGCA/D), and myotonic dystrophy, dilated cardiomyopathy, conduction disorders, and arrhythmias develop and can cause sudden death.

Joint abnormalities: In congenital muscular dystrophies and congenital myopathies, joint contractures may appear at birth or early on. In collagen VI deficiency (Ullrich muscular dystrophy), a distinctive pattern with coexisting distal joint hypermobility and proximal joint contractures is observed.

Muscle pain and cramps: Generally not prominent in hereditary myopathies, but exercise-induced muscle cramps·myalgia occur in metabolic myopathies and some channelopathies.

7. Signs

Physical examination findings differ by subtype and stage, but the following signs are important in general myopathy practice.

Muscle strength testing findings: Quantified using the MRC scale; in most cases proximal (deltoid, iliopsoas, quadriceps) weakness is prominent earlier than distal (finger extensors, ankle dorsiflexors) weakness. Weakness below grade 4 in the proximal limbs with relatively preserved deep tendon reflexes is the typical pattern (a point of distinction from neurogenic lesions).

Gowers sign: A maneuver in which, owing to weakness of the quadriceps and hip muscles, the patient pushes on the legs with the hands to stand up from the floor. It is typical in childhood-onset myopathies such as DMD but can also be observed in adult-onset LGMD.

Scapular winging: A finding in which the scapula lifts away from the chest wall owing to weakness of the serratus anterior and lower trapezius. It is prominent in FSHD, dysferlinopathy (Miyoshi type, LGMD2B), and some congenital myopathies.

Pseudohypertrophy: A phenomenon in which muscle volume appears instead to increase as functional muscle tissue is replaced by fat·connective tissue. Calf pseudohypertrophy is typical in DMD and is also observed in some LGMDs.

Joint contractures and spinal deformity: Achilles tendon shortening, elbow·knee flexion contractures, and scoliosis appear as the disease progresses. Because scoliosis further adversely affects respiratory function, early detection and orthopedic monitoring are important.

Cardiopulmonary findings: Heart murmurs and arrhythmias may be detected on auscultation. On respiratory testing, reduced vital capacity (FVC) and reduced supine FVC are indicators of early respiratory muscle involvement.

Facial findings: Frontal balding, a long face, and temporalis atrophy characteristic of myotonic dystrophy; the mask-like facial expression of FSHD; and ptosis due to ocular muscle paralysis are diagnostic clues to specific subtypes.

Specific muscle patterns: Muscle MRI visualizes the pattern of fatty infiltration by muscle group and is useful for subtype differentiation. For example, a pattern of fatty infiltration in the posterior thigh muscle group is characteristic of LGMD R9 (FKRP), and in the central part of the rectus femoris in Bethlem myopathy.

8. Screening

Screening for hereditary myopathies aims at identifying high-risk individuals before symptom onset and at early diagnosis.

Serum creatine kinase (CK) measurement: The most sensitive serum marker of muscle damage. In DMD and LGMD (DYSF, CAPN3, etc.), which involve severe sarcolemmal damage, it rises to tens to hundreds of times normal. On the other hand, in congenital myopathies (RYR1, NEB, etc.) and some Emery-Dreifuss muscular dystrophy, CK is only normal to mildly elevated, so a normal CK is not a criterion for excluding myopathy. In myotonic dystrophy, CK also shows mild to moderate elevation. CK measurement is inexpensive and immediately available in the outpatient setting, so it must be performed at the initial visit.

Neonatal metabolic screening: Pompe disease (acid alpha-glucosidase deficiency) is included in the Korean newborn screening panel, so blood enzyme activity is measured early after birth. Measurement of GAA enzyme activity using dried blood spots (DBS) enables early diagnosis of infantile Pompe disease and early initiation of enzyme replacement therapy (ERT).

Electromyography (EMG) and nerve conduction studies (NCS): Used to confirm myopathic changes (short motor unit potentials, early full recruitment, fibrillation potentials) and to distinguish them from neurogenic diseases. Identification of myotonic discharges suggests myotonic dystrophy or nondystrophic myotonia.

Muscle MRI: The pattern of fatty infiltration of lower limb muscle groups is confirmed on STIR·T1-weighted images. It is used at the prediagnostic stage to select the muscle biopsy site and to set the direction of subtype differentiation. Because there is no radiation exposure, it is also useful in pediatric patients.

Family history-based screening: In first-degree relatives of confirmed patients, CK and targeted genetic testing (based on the confirmed causative gene) are performed to detect asymptomatic carriers or mild presentations early. This is important for early initiation of preventive cardiac monitoring (Emery-Dreifuss, LMNA) and respiratory monitoring.

9. Diagnosis

Diagnosis of hereditary myopathies is made by integrating clinical, electrophysiological, imaging, pathological, and genetic information, and it is rarely completed by a single test alone.

Muscle biopsy: An open or needle biopsy is performed on an appropriate muscle (one that is clinically weak but not at end-stage atrophy). Fresh frozen sections are used for tissue processing. Evaluation techniques include the following. ① Histochemical stains such as hematoxylin-eosin (H&E), NADH-TR, SDH, PAS, and oil-red-O: identify central nuclei, inclusion bodies, necrotic·regenerating muscle fibers, fat·glycogen deposition, etc. ② Immunofluorescence/immunohistochemistry: identify protein expression patterns of dystrophin (N-terminal, C-terminal, rod domain), sarcoglycans (α·β·γ·δ), dysferlin, calpain-3, merosin (LAMA2), COLVI, emerin, dysferlin, etc. ③ Electron microscopy: ultrastructural abnormalities such as nemaline rods, mitochondrial abnormalities (ragged red fibers, COX deficiency), and autophagosome accumulation. Muscle biopsy results support interpretation of the significance of variants found by NGS and, in some cases, confirm the diagnosis on their own.

Next-generation sequencing (NGS): Currently the core tool of clinical diagnosis. A three-step strategy of a myopathy gene panel (50–300 genes), whole exome sequencing (WES), and whole genome sequencing (WGS) is used. The diagnostic yield of a myopathy panel is 40–60% when the clinical phenotype is clear, WES is at a similar level, and WGS can further increase the diagnostic yield by also detecting variants in noncoding regions, structural variants, and repeat expansions. Variant types not detectable by standard NGS, such as in FSHD (detection of D4Z4 repeat contraction), are analyzed separately by Southern blot, repeat-primed PCR, etc.

Additional biochemical and enzyme tests: GAA enzyme activity for Pompe disease (leukocytes or skin fibroblasts), measurement of respiratory chain complex activity for mitochondrial myopathy, and assessment of intracellular ManNAc levels when a GNE mutation is suspected are performed selectively.

Cardiopulmonary function assessment: Myocardial involvement is assessed with electrocardiography (ECG), 24-hour Holter monitoring, and echocardiography (ECHO), and respiratory function is monitored regularly with pulmonary function tests (PFT, especially FVC and supine FVC) and polysomnography (PSG).

10. Treatment

Treatment of hereditary myopathies is divided into targeted therapy according to the causative gene and subtype-nonspecific supportive·rehabilitation treatment.

Disease-modifying therapy: ① Pompe disease (including LGMD R16): enzyme replacement therapy (ERT) with alglucosidase alfa (Myozyme®) or the highly purified avalglucosidase alfa (Nexviazyme®) markedly prolongs survival in the infantile form and is also effective in maintaining respiratory function·muscle strength in the late-onset adult form. ② DMD: exon-skipping agents (eteplirsen, golodirsen, viltolarsen — skipping of exons 51, 53, 45), stop codon readthrough (ataluren, nonsense variants), and steroids (prednisone 0.75 mg/kg/day or deflazacort) are standard treatment. Gene therapy (delandistrogene moxeparvovec, SRP-9001) has been approved in some countries. ③ Myotonic dystrophy: mexiletine is used to relieve myotonia.

Rehabilitation and orthotic treatment: In all subtypes, physical therapy and occupational therapy are central to maintaining muscle strength and preserving function. Resistance exercise has been shown to be safe in some subtypes (FSHD, LGMD), but caution is needed because high-intensity eccentric exercise can cause CK surges and muscle fiber damage. Ankle-foot orthoses (AFO), wheelchairs, powered assistive devices, and proximal orthoses are important for maintaining mobility.

Respiratory support: Noninvasive positive pressure ventilation (NIPPV, BiPAP) is started when FVC <50% or nocturnal hypoxemia is present. Aspiration prevention and cough assist devices (MI-E, cough assist) are essential for preventing infectious pneumonia. In progressive respiratory failure, tracheostomy and invasive ventilation are also considered.

Cardiac management: In Emery-Dreifuss, LMNA, and some LGMDs, early administration of ACE inhibitors/ARBs and beta-blockers slows the progression of dilated cardiomyopathy. In atrial fibrillation or high-grade atrioventricular block, antiarrhythmic drugs, a permanent pacemaker, or implantation of a defibrillator (ICD) is required.

Spinal and orthopedic treatment: Surgical correction is considered when scoliosis progresses beyond a Cobb angle of 20–25°. For joint contractures, regular stretching, night splints, and in some cases tendon lengthening are performed.

Swallowing function: In dysphagia, nutrition is supported with dietary modification (texture-modified diet), a nasogastric tube, or percutaneous endoscopic gastrostomy (PEG).

11. Prognosis

The prognosis of hereditary myopathies varies greatly according to the causative gene, clinical subtype, age of onset, and presence of respiratory·cardiac involvement. In general, the earlier the age of onset and the earlier the involvement of respiratory and cardiac muscles, the poorer the prognosis.

Without treatment, DMD was a disease leading to loss of ambulation in the teens to 20s and death from respiratory or cardiac failure in the 20s to 30s, but with steroid treatment and improved respiratory management, mean life expectancy has been greatly extended, and survival into the 30s–40s is now becoming common. With the introduction of gene therapy, prognosis is expected to improve further. Becker muscular dystrophy has a slower course than DMD, and ambulation is often maintained into the 40s–50s.

LGMD differs greatly by subtype. CAPN3 (LGMD R1) shows slow progression, and independent ambulation is sometimes maintained for decades, whereas DYSF (LGMD R2) is also relatively slow but can lead to loss of ambulation in the 40s–50s. In the adult form of myotonic dystrophy (DM1), quality of life is reduced and life expectancy is shortened because of systemic complications (ECG abnormalities, cataracts, insulin resistance, cognitive decline). In mitochondrial myopathies, functional decline can progress rapidly when metabolic crises recur.

Early detection and active management of cardiopulmonary complications and continuous rehabilitation are the most important prognostic factors for maintaining function and prolonging survival. Integrated management by a multidisciplinary team (neurology, pulmonology, cardiology, rehabilitation medicine, orthopedics, genetic counselors, social workers) is key to improving prognosis.

12. Prevention

Because hereditary myopathies are caused by single-gene defects, primary prevention focuses on genetic counseling and reproductive choices.

Genetic counseling: Families of confirmed patients are provided with professional counseling on the inheritance pattern, recurrence risk, carrier testing, and preimplantation·prenatal diagnosis. In autosomal recessive inheritance, couples in whom both parents are confirmed carriers have a 25% recurrence risk with each pregnancy. In X-linked inheritance, female carriers transmit the disease to sons with 50% probability.

Preimplantation Genetic Testing (PGT): During in vitro fertilization, the causative variant is analyzed at the embryo stage and only normal or carrier embryos are transferred. It is a technically mature method and the most effective means of preventing disease recurrence in families with an indication.

Prenatal diagnosis: Fetal genes are analyzed by chorionic villus sampling (10–12 weeks) or amniocentesis (15–18 weeks). It is performed in families in which the causative variant has already been identified, and the couple decides autonomously whether to continue the pregnancy based on the results.

Screening of asymptomatic carriers and family members with early presentation: Because some women who are carriers of DMD exon duplications/deletions also develop dilated cardiomyopathy, regular cardiac checkups are recommended. Carriers of genes that may be accompanied by ECG abnormalities, such as LMNA and KCNJ2, undergo regular ECG·Holter monitoring for arrhythmia surveillance.

Expansion of newborn screening: For diseases such as Pompe disease, in which early initiation of treatment markedly improves prognosis, newborn screening has a preventive effect. Expansion of newborn screening to more neuromuscular diseases, such as SMA and DMD, is being discussed.

Prevention of secondary complications: After diagnosis, the key to secondary prevention is preventing respiratory infections with vaccination (influenza, pneumococcus) and minimizing complications through early surveillance for cardiopulmonary complications.

13. References

  1. Sewry CA, Laitila JM, Wallgren-Pettersson C. Nemaline myopathies: a current view. J Muscle Res Cell Motil. 2019;40(2):111–126. PMID: 31209641
  2. Straub V, Murphy A, Udd B; LGMD workshop study group. 229th ENMC international workshop: Limb girdle muscular dystrophies – Nomenclature and reformed classification Naarden, the Netherlands, 17–19 March 2017. Neuromuscul Disord. 2018;28(8):702–710. PMID: 30055862
  3. Bönnemann CG, Wang CH, Quijano-Roy S, et al. Diagnostic approach to the congenital muscular dystrophies. Neuromuscul Disord. 2014;24(4):289–311. PMID: 24581957
  4. van der Maarel SM, Frants RR, Padberg GW. Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta. 2007;1772(2):186–194. PMID: 17005390
  5. Liewluck T, Milone M. Untangling the complexity of limb-girdle muscular dystrophies. Muscle Nerve. 2018;58(2):167–177. PMID: 29350770
  6. Nigro V, Savarese M. Genetic basis of inherited myopathies and cardiomyopathies. Curr Opin Neurol. 2019;32(5):637–644. PMID: 31246620
  7. Preisler N, Haller RG, Vissing J. Exercise in muscle glycogen storage diseases. J Inherit Metab Dis. 2015;38(3):551–563. PMID: 25108457
  8. Mercuri E, Muntoni F. Muscular dystrophies. Lancet. 2013;381(9869):845–860. PMID: 23465426
  9. Witting N, Vissing J. Pharmacologic treatment of downstream pathological processes in muscle diseases. Expert Opin Pharmacother. 2019;20(10):1231–1240. PMID: 31081393
  10. Ghaoui R, Cooper ST, Lek M, et al. Use of whole-exome sequencing for diagnosis of limb-girdle muscular dystrophy. JAMA Neurol. 2015;72(12):1–9. PMID: 26436725